Unknown

Dataset Information

0

Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen.


ABSTRACT: Auger electron emitters such as (125)I have a high linear energy transfer and short range of emission (<10 ?m), making them suitable for treating micrometastases while sparing normal tissues. We used a highly specific small molecule targeting the prostate-specific membrane antigen (PSMA) to deliver (125)I to prostate cancer cells.The PSMA-targeting Auger emitter 2-[3-[1-carboxy-5-(4-(125)I-iodo-benzoylamino)-pentyl]-ureido]-pentanedioic acid ((125)I-DCIBzL) was synthesized. DNA damage (via phosphorylated H2A histone family member X staining) and clonogenic survival were tested in PSMA-positive (PSMA+) PC3 PIP and PSMA-negative (PSMA-) PC3 flu human prostate cancer cells after treatment with (125)I-DCIBzL. Subcellular drug distribution was assessed with confocal microscopy using a related fluorescent PSMA-targeting compound YC-36. In vivo antitumor efficacy was tested in nude mice bearing PSMA+ PC3 PIP or PSMA- PC3 flu flank xenografts. Animals were administered (intravenously) 111 MBq (3 mCi) of (125)I-DCIBzL, 111 MBq (3 mCi) of (125)I-NaI, an equivalent amount of nonradiolabeled DCIBzL, or saline.After treatment with (125)I-DCIBzL, PSMA+ PC3 PIP cells exhibited increased DNA damage and decreased clonogenic survival when compared with PSMA- PC3 flu cells. Confocal microscopy of YC-36 showed drug distribution in the perinuclear area and plasma membrane. Animals bearing PSMA+ PC3 PIP tumors had significant tumor growth delay after treatment with (125)I-DCIBzL, with only 1 mouse reaching 5 times the initial tumor volume by 60 d after treatment, compared with a median time to 5 times volume of less than 15 d for PSMA- PC3 flu tumors and all other treatment groups (P = 0.002 by log-rank test).PSMA-targeted radiopharmaceutical therapy with the Auger emitter (125)I-DCIBzL yielded highly specific antitumor efficacy in vivo, suggesting promise for treatment of prostate cancer micrometastases.

SUBMITTER: Kiess AP 

PROVIDER: S-EPMC4634552 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen.

Kiess Ana P AP   Minn Il I   Chen Ying Y   Hobbs Robert R   Sgouros George G   Mease Ronnie C RC   Pullambhatla Mrudula M   Shen Colette J CJ   Foss Catherine A CA   Pomper Martin G MG  

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20150716 9


<h4>Unlabelled</h4>Auger electron emitters such as (125)I have a high linear energy transfer and short range of emission (<10 μm), making them suitable for treating micrometastases while sparing normal tissues. We used a highly specific small molecule targeting the prostate-specific membrane antigen (PSMA) to deliver (125)I to prostate cancer cells.<h4>Methods</h4>The PSMA-targeting Auger emitter 2-[3-[1-carboxy-5-(4-(125)I-iodo-benzoylamino)-pentyl]-ureido]-pentanedioic acid ((125)I-DCIBzL) was  ...[more]

Similar Datasets

| S-EPMC7053212 | biostudies-literature
| S-EPMC7383930 | biostudies-literature
| S-EPMC3111331 | biostudies-literature
| S-EPMC6805467 | biostudies-literature
| S-EPMC5581714 | biostudies-literature
| S-EPMC9454275 | biostudies-literature
| S-EPMC10285561 | biostudies-literature
| S-EPMC3201799 | biostudies-literature
| S-EPMC8575563 | biostudies-literature
| S-EPMC7865627 | biostudies-literature